[Expert consensus on perioperative management of tooth extraction in patients receiving denosumab therapy].

Li Ye, Yubin Cao, Guowen Sun, Yang Xue, Nianhui Cui, Yu Cai, Duohong Zou, Haikuo Tang, Yanjia Hu, Ting Luo, Lei Sun, Zhongcheng Gong, Fudong Zhu, Fugui Zhang, Meng You, Yuxing Guo, Yujiang Wang, Liao Wang, Songling Chen, Bing Han, Wei Zhang, Qing Zhou, Yue He, Jihong Zhao, Kaijin Hu, Lei Liu, Jiyuan Liu, Jian Pan
{"title":"[Expert consensus on perioperative management of tooth extraction in patients receiving denosumab therapy].","authors":"Li Ye, Yubin Cao, Guowen Sun, Yang Xue, Nianhui Cui, Yu Cai, Duohong Zou, Haikuo Tang, Yanjia Hu, Ting Luo, Lei Sun, Zhongcheng Gong, Fudong Zhu, Fugui Zhang, Meng You, Yuxing Guo, Yujiang Wang, Liao Wang, Songling Chen, Bing Han, Wei Zhang, Qing Zhou, Yue He, Jihong Zhao, Kaijin Hu, Lei Liu, Jiyuan Liu, Jian Pan","doi":"10.7518/hxkq.2026.2025418","DOIUrl":null,"url":null,"abstract":"<p><p>Denosumab is a humanized monoclonal antibody targeting receptor activator of nuclear factor-κB ligand (RANKL) and is commonly used in the treatment of osteoporosis and cancer-related bone metastases. However, the persistent use of denosumab has been associated with an increasing incidence of denosumab-related osteonecrosis of the jaw (DRONJ), particularly following tooth extraction. This expert consensus aims to develop clinical management guidelines for the perioperative period of tooth extraction in patients who are currently receiving or have previously received denosumab therapy. The consensus covers the definition, etiology, epidemiology, staging, and risk factors of DRONJ, focusing on preoperative assessment, risk-based prevention strategies, minimally invasive surgical techniques, and postoperative follow-up protocols. The core management strategy for DRONJ emphasizes individualized decision-making based on a comprehensive preoperative assessment of medication history, local infection, and systemic conditions. The main risk factors for DRONJ include high-dose and long-term denosumab therapy, preexisting oral infections, such as periodontitis and periapical periodontitis, and invasive dental procedures, including tooth extraction, diabetes, and concomitant use of glucocorticoids or antiangiogenic agents. Core preventive measures include strict perioperative oral care, risk assessment-based antibiotic prophylaxis, long-term drug holidays, which were developed by dentists and physicians prio-ritizing the primary disease, and minimally invasive surgical techniques for managing trauma, preserving local blood supply, thoroughly removing infected tissues, and ensuring tight wound closure. This consensus highlights the importance of multidisciplinary collaboration between dental and clinical medicine experts in managing DRONJ. High-quality research is necessary to provide an evidence-based foundation for optimizing DRONJ prevention and treatment strategies.</p>","PeriodicalId":94028,"journal":{"name":"Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology","volume":"44 2","pages":"153-172"},"PeriodicalIF":0.0000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13047874/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7518/hxkq.2026.2025418","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Denosumab is a humanized monoclonal antibody targeting receptor activator of nuclear factor-κB ligand (RANKL) and is commonly used in the treatment of osteoporosis and cancer-related bone metastases. However, the persistent use of denosumab has been associated with an increasing incidence of denosumab-related osteonecrosis of the jaw (DRONJ), particularly following tooth extraction. This expert consensus aims to develop clinical management guidelines for the perioperative period of tooth extraction in patients who are currently receiving or have previously received denosumab therapy. The consensus covers the definition, etiology, epidemiology, staging, and risk factors of DRONJ, focusing on preoperative assessment, risk-based prevention strategies, minimally invasive surgical techniques, and postoperative follow-up protocols. The core management strategy for DRONJ emphasizes individualized decision-making based on a comprehensive preoperative assessment of medication history, local infection, and systemic conditions. The main risk factors for DRONJ include high-dose and long-term denosumab therapy, preexisting oral infections, such as periodontitis and periapical periodontitis, and invasive dental procedures, including tooth extraction, diabetes, and concomitant use of glucocorticoids or antiangiogenic agents. Core preventive measures include strict perioperative oral care, risk assessment-based antibiotic prophylaxis, long-term drug holidays, which were developed by dentists and physicians prio-ritizing the primary disease, and minimally invasive surgical techniques for managing trauma, preserving local blood supply, thoroughly removing infected tissues, and ensuring tight wound closure. This consensus highlights the importance of multidisciplinary collaboration between dental and clinical medicine experts in managing DRONJ. High-quality research is necessary to provide an evidence-based foundation for optimizing DRONJ prevention and treatment strategies.

【接受地诺单抗治疗患者拔牙围手术期处理的专家共识】。
Denosumab是一种靶向核因子-κB配体受体激活剂(RANKL)的人源化单克隆抗体,常用于治疗骨质疏松症和癌症相关的骨转移。然而,持续使用denosumab与denosumab相关性颌骨骨坏死(DRONJ)的发生率增加有关,特别是在拔牙后。本专家共识旨在为目前正在接受或曾经接受过denosumab治疗的患者的拔牙围手术期制定临床管理指南。共识涵盖了DRONJ的定义、病因、流行病学、分期和危险因素,重点是术前评估、基于风险的预防策略、微创手术技术和术后随访方案。DRONJ的核心管理策略强调基于综合术前用药史、局部感染和全身状况评估的个性化决策。DRONJ的主要危险因素包括大剂量和长期地诺单抗治疗、既往口腔感染(如牙周炎和根尖周炎)、侵入性牙科手术(包括拔牙)、糖尿病以及同时使用糖皮质激素或抗血管生成药物。核心预防措施包括严格的围手术期口腔护理、基于风险评估的抗生素预防、长期药物休假(由牙医和医生制定,优先考虑原发疾病),以及微创手术技术,用于处理创伤、保持局部血液供应、彻底清除感染组织和确保伤口紧密闭合。这一共识强调了牙科和临床医学专家在管理DRONJ方面多学科合作的重要性。有必要开展高质量的研究,为优化DRONJ防治策略提供循证基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书